Aktuellt
SENASTE
Redeye gives a short comment on Remedy’s H1 2022 report. Revenue was somewhat weaker than expected, approximately 6% weaker. The cost-base was relatively in line with our expectations. With no production capitalization during the quarter the EBIT was below our estimate. Redeye estimates the development fees and thus the revenue will increase gradually from this level.
LÄS MER
